The primary objectives of the study are to obtain clinically meaningful data on survival and outcomes of all the patients with spinal muscular atrophy (SMA) 5q types 1 through 4 (according to international classification), being followed in the reference centers of the disease in France between September 1, 2016 and August 31, 2024. The registry will collect retrospectively and prospectively the longitudinal data of the long-term follow-up for child and adult patients, under real life conditions of current medical practice, in order to document the clinical evolution of patients (survival, motor, respiratory, orthopedic and nutritional), the conditions of use of the treatments, the mortality rates of treated and untreated patients, the tolerance of the treatments, adverse events in order to better define their places in the therapeutic strategy.
As secondary objectives, the study aims: * to estimate the frequencies of patients with SMA 5q types 1 through 4 who have being treated in the reference centers between September 1 2016 and August 31 2024; * to describe overall demographic, familial, clinical, biological, and genetic characteristics of SMA 5q patients treated in all regions of France, by the type of SMA (type 1,2,3, and 4); * to study the impact of proactive and symptomatic medical interventions (bracing, IPPB devices) and medications (vaccinations, anti-infectious, digestive, nutritional supplements) in the evolution of patients; * to study the long-term evolution (survival, motor and respiratory functions, spinal shape, growth and nutritional function) of SMA 5q in treated and untreated populations, by new available therapies, throughout the register; * to study mortality rate of SMA 5q in treated and untreated populations, by new available therapies, throughout the register; * to identify and document the different therapeutic strategies by sub-populations and by discontinuation or follow-up of treatments; * to evaluate prognostic factors of responses to therapies; * to study the tolerance of treatments by type of treatments, by type of SMA and overall tolerance (including adverse events); * to estimate the costs of care for SMA 5q patients in different groups (types, ages); * to provide needful elements to evaluate the health care costs for the disease; * to study the autonomy and the quality of life of patients depending on different therapeutic strategies; * to study the impact of the disease on caregivers; * to facilitate development of scientific research on SMA in the conduct of trials on new therapeutic strategies.
Study Type
OBSERVATIONAL
Enrollment
1,000
Unité neuromusculaire, Service de Neurologie et Réanimation Pédiatrique, (French neuromuscular reference network (FILNEMUS), Hôpital Raymond Poincaré,
Garches, France
RECRUITINGMotor functional development or status
* SMA Type 1 until 2 years of age: change of HINE (Hammersmith Infant Neurological Examination) score * Children: change in Vignos and Brooke scores (level of upper and Lower extremities autonomy) * Adults: change in Walton \& Boston scores (level of upper and Lower extremities autonomy)
Time frame: baseline, 1 year, 2 year, 3 year, 4 year, 5 year, 6 year, 7 year, 8 year and 9 year
Motor function scores
* For children ≤ 2 years: change of CHOP INTEND (Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders) score will be evaluated * For children between 2 and 5 years, ambulatory or not: Change of total MFM-20 (Motor Function Measure 20) score will be evaluated. Change of 3 dimension scores will be evaluated: D1 (start and transfers station), D2 (axial and proximal motricity) and D3 (distal including the upper limb) * For children children \> 6 years and adults, ambulatory or not: Change of total MFM-32 (Motor Function Measure 32) score will be evaluated. Change of 3 dimension scores will be evaluated: D1 (start and transfers station), D2 (axial and proximal motricity) and D3 (distal including the upper limb). * For ambulatory individuals: added 6MWT (6 minutes walking test)
Time frame: baseline, 1 year, 2 year, 3 year, 4 year, 5 year, 6 year, 7 year, 8 year and 9 year
Yearly changes of morbi-mortality-vital events
Events of hospitalizations, recurrent infections, fractures, complications and death.
Time frame: 9 years
Respiratory events
Onset of respiratory support or change in the mode and time (including intubations).
Time frame: baseline, 1 year, 2 year, 3 year, 4 year, 5 year, 6 year, 7 year, 8 year and 9 year
Digestive-nutritional events
Digestive events, onset of nutritional support or change in the mode and time
Time frame: baseline, 1 year, 2 year, 3 year, 4 year, 5 year, 6 year, 7 year, 8 year and 9 year
Yearly changes of spinal events
Onset of spinal deformity, or increment of 5° or more in the Cobb angle (examination in supine position without brace ; if sitting possible, examination in the upright position, with or without brace or with or without implant (surgery)
Time frame: 9 years
Frequency
Frequencies of patients with SMA 5q of type 1,2,3 and 4 cared in the reference centres between September 1 2016 and August 31 2024.
Time frame: through study completion, an average of 9 year
Responses to the treatments (nusinersen and salbutamol)
Responses of the primary outcome measures to the therapies (salbutamol, nusinersen, onasemnogene, risdiplam)
Time frame: 1 year, 2 year, 3 year, 4 year, 5 year, 6 year, 7 year, 8 year and 9 year
Spinal status
Evolution of scoliosis (Cobb angle) in the preoperative period (patients treated vs not treated with Garches brace): first and last Cobb angle (and ages)
Time frame: 1 year, 2 year, 3 year, 4 year, 5 year, 6 year, 7 year, 8 year and 9 year
Impact of spinal surgery techniques in scoliosis
Impact of spinal surgery techniques in scoliosis (presurgical and last post surgical Cobb angle)
Time frame: 1 year, 2 year, 3 year, 4 year, 5 year, 6 year, 7 year, 8 year and 9 year
Mortality
For treated and untreated patients. Rate of mortality will be assessed at 1,2 and 5 years.
Time frame: at 1, 2 and 5 years
Pulmonary function
Forced vital capacity (FVC) will be evaluated at least once per year for children \> 5 years, by specifying the posture of realization of the test, lying vs sitting.
Time frame: at 6 months
Respiratory muscles performance
Peak expiratory and inspiratory pressures will be evaluated if possible for children \> 5 years (MEP, MIP, PF, SNIP (sniff nasal inspiratory pressure)
Time frame: at 6 months
Pulmonary function
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
PCF (peak cough flow) will be evaluated at least once per year for children \> 5 years, by specifying the posture of realization of the test, lying vs sitting.
Time frame: at 6 months
Cardiological parameter
ECG abnormality will be evaluated by Holter ECG 24h: P Wave, QRS Complex, QT Interval
Time frame: through study completion, an average of 9 year
Cardiological function and anatomy
Anatomic abnormalities will be evaluated by echocardiography.
Time frame: through study completion, an average of 9 year
Biomarkers
Change of biomarkers: Neurofilaments and CPK
Time frame: baseline, 1 year, 2 year, 3 year, 4 year, 5 year, 6 year, 7 year, 8 year and 9 year
Patient's quality of life: PedsQL (Pediatric Quality of Life Inventory) Child report
Questionary as the "PedsQL Child report" will be used to evaluate patient's quality of life. Total Scale Score: 0.88 Child Self-Report; 0.90 Parent Proxy-Report.
Time frame: baseline, 1 year, 2 year, 3 year, 4 year, 5 year, 6 year, 7 year, 8 year and 9 year
Patient's quality of life: PedsQL parent report concerning child
Questionary as the "PedsQL parent report concerning child" will be used to evaluate patient's quality of life. Total Scale Score: 0.88 Child Self-Report; 0.90 Parent Proxy-Report.
Time frame: baseline, 1 year, 2 year, 3 year, 4 year, 5 year, 6 year, 7 year, 8 year and 9 year
Patient's quality of life: QoL-gNMD for adult
Questionary as "QoL-gNMD for adult" (Quality of Life in genetic Neuromuscular Disease) will be used to evaluate patient's quality of life.
Time frame: baseline, 1 year, 2 year, 3 year, 4 year, 5 year, 6 year, 7 year, 8 year and 9 year
Caregiver burden assessement
Questionnaire as "Work Productivity and Activity Impairment Questionnaire SMAv2" will be completed once a year by a member of neuromuscular center or patients or their relatives.
Time frame: at baseline, 1 year, 2 year, 3 year, 4 year, 5 year, 6 year, 7 year, 8 year and 9 year
Caregiver burden assessement
Questionnaire as "FICD+4 Burden Interview Questionnaire" will be completed once a year by a member of neuromuscular center or patients or their relatives. FICD (Family Impact of Childhood Disability)+4 Burden Interview Questionnaire: the multidimensional measurements to assess the impacts on time, expenses, work, relationships and health of caregiver.
Time frame: at baseline, 1 year, 2 year, 3 year, 4 year, 5 year, 6 year, 7 year, 8 year and 9 year